Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma

OBJECTIVES:

Primary

- To evaluate the efficacy of single agent dinaciclib in patients with relapsed or
refractory multiple myeloma.

Secondary

- To evaluate the toxicities associated with dinaciclib in these patients.

- To evaluate the response duration and progression-free survival among these patients.

- To study the effect of dinaciclib on myeloma cell proliferation and apoptotic rates.

- To assess the ability of dinaciclib to inhibit drug targets (cyclin-dependent kinases
in the myeloma cell).

OUTLINE: This is a multicenter, dose escalation study.

Patients receive dinaciclib IV over 2 hours on day 1. Courses repeat every 21 days in the
absence of disease progression or unacceptable toxicity.

Blood and bone marrow samples are collected periodically for correlative studies.

After completion of study treatment, patients are followed up for up to 3 years.